RBC Capital Maintains Outperform on Biogen, Raises Price Target to $260

Benzinga · 2d ago
RBC Capital analyst Brian Abrahams maintains Biogen (NASDAQ:BIIB) with a Outperform and raises the price target from $240 to $260.